ATC Group: L03AX14 Histamine dihydrochloride

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L03AX14 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L03 Immunostimulants
3 L03A Immunostimulants
4 L03AX Other immunostimulants
5 L03AX14 Histamine dihydrochloride

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
PAREN - Parenteral 0.5 mg

Active ingredients in L03AX14

Active Ingredient Description
Histamine

Histamine/IL-2 is an immunotherapy which aims to induce immune-mediated destruction of residual myeloid leukaemic cells and thereby to prevent relapse of leukaemia. The role of histamine is to protect lymphocytes, in particular NK cells and T cells, which are responsible for the immune-mediated destruction of residual leukaemic cells.

Related product monographs

Title Information Source Document Type  
CEPLENE Solution for injection European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

Austria (AT)

Croatia (HR)

Estonia (EE)

Ireland (IE)

Lithuania (LT)

Poland (PL)

Romania (RO)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.